Consistent with our study, Mizukami et al. [209] demonstrated that MSLN KO or blockade with the clinical anti-MSLN monoclonal antibody amatuximab can delay intraperitoneal tumor growth in the presence or absence of intact immune signaling. The gene discussed is MSLN; the disease is neoplasm.